Ken Fisher’s AnaptysBio ANAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.14M Buy
56,596
+32
+0.1% +$1.72K ﹤0.01% 515
2025
Q4
$2.74M Sell
56,564
-2,314
-4% -$90.2K ﹤0.01% 526
2025
Q3
$1.8M Sell
58,878
-21
-0% -$482 ﹤0.01% 592
2025
Q2
$1.31M Buy
58,899
+21
+0% +$440 ﹤0.01% 648
2025
Q1
$1.09M Hold
58,878
﹤0.01% 664
2024
Q4
$780K Sell
58,878
-3,070
-5% -$74.4K ﹤0.01% 701
2024
Q3
$2.08M Sell
61,948
-3,044
-5% -$104K ﹤0.01% 577
2024
Q2
$1.63M Sell
64,992
-5,662
-8% -$132K ﹤0.01% 619
2024
Q1
$1.59M Sell
70,654
-500
-0.7% -$11.8K ﹤0.01% 632
2023
Q4
$1.52M Buy
71,154
+500
+0.7% +$8.62K ﹤0.01% 634
2023
Q3
$1.27M Hold
70,654
﹤0.01% 701
2023
Q2
$1.44M Hold
70,654
﹤0.01% 709
2023
Q1
$1.54M Sell
70,654
-6,896
-9% -$168K ﹤0.01% 693
2022
Q4
$2.4M Hold
77,550
﹤0.01% 620
2022
Q3
$1.98M Buy
77,550
+10
+0% +$234 ﹤0.01% 575
2022
Q2
$1.57M Buy
77,540
+9,651
+14% +$214K ﹤0.01% 565
2022
Q1
$1.68M Buy
67,889
+8,468
+14% +$256K ﹤0.01% 575
2021
Q4
$2.06M Buy
59,421
+13,402
+29% +$425K ﹤0.01% 553
2021
Q3
$1.25M Buy
+46,019
New +$1.17M ﹤0.01% 581

Other funds holding ANAB

Ken Fisher's ANAB Position: Q1 2026 in Review

Ken Fisher increased its AnaptysBio (ANAB) stake by 0.06% in Q1 2026, buying an estimated $1.72K and bringing the position to 56,596 shares worth $3.14M. The position accounts for ﹤0.01% of the portfolio, ranked #515.

Ken Fisher first reported a position in ANAB in Q3 2021 and has held it in 19 quarters since. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Ken Fisher held 56,596 shares of AnaptysBio worth $3.14M as of Q1 2026.
  • Ken Fisher bought 32 AnaptysBio shares in Q1 2026, an estimated $1.72K.
  • AnaptysBio made up ﹤0.01% of Ken Fisher's portfolio in Q1 2026, its #515 holding.
  • Ken Fisher first reported a position in AnaptysBio in Q3 2021 and has held it in 19 quarters since.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.